Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

GCDx is not partnered with Radient.

GCDx is trying to get $1.5 million funding. IF they get that funding, they will sign a license agreement with Radient.

Even then, signing a license agreement does not constitute partnership.

If the Onko Sure process is currently patented, GCDx cannot manufacture the test without that license agreement, which means they will not be selling the test on August 1st unless you see an 8-K for a GCDx license agreement before then.

And that 8-K, if it appears, is going to have a bankruptcy clause that wasn't in the 2012 license agreement.

But how can anyone make a significant number of the tests without a replacement for the anti-fibrinogen HRP? How can UNI do it, or GCDx, or anyone in China?